Supplements Don't Measurably Increase Macular Pigment Density

Share this content:
Supplements Don't Measurably Increase Macular Pigment Density
Supplements Don't Measurably Increase Macular Pigment Density

FRIDAY, Sept. 29, 2017 (HealthDay News) -- Dietary supplementation does not lead to measurable increases in macular pigment optical density, according to a study published online Sept. 28 in JAMA Ophthalmology.

Jean-François Korobelnik, M.D., from Centre Hospitalier Universitaire Bordeaux in France, and colleagues randomized 120 individuals who were first-generation offspring of parents with neovascular age-related macular degeneration and were free of any ocular or retinal disease to receive either two daily dietary supplementation capsules (containing lutein, zeaxanthin, ω-3 polyunsaturated fatty acids, and vitamins), or placebo for six months.

The researchers found that there was a statistically significant increase in plasma lutein and zeaxanthin in the lutein plus zeaxanthin group after three months and six months of treatment versus the placebo group. However, the difference in macular pigment optical density (MPOD) change, measured by the Heidelberg Retina Angiograph at 0.98 degrees eccentricity between six months and baseline, was 0.036 (P = 0.33).

"Further research is necessary to understand the mechanism of absorption and metabolism of these nutrients in the macula, the best way to measure MPOD, and the clinical benefit for the patients," conclude the authors.

Two authors disclosed financial ties to pharmaceutical companies, including Laboratoires Théa, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »